MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-12-31.

Income Overview

Net Income
$2,434,672
EPS
-$0.77
Unit: Dollar

Income Statement
2025-12-31
2025-09-30
2025-06-30
2025-03-31
Research and development
697,723 3,785,649 3,975,522* 1,616,011
General and administrative
2,126,918 1,867,040 1,719,467.5* 1,406,796
Restructuring costs
1,236,172 ---
Total operating expenses
4,060,813 5,652,689 5,694,989.5* 3,022,807
License revenue
---7,844,624.5* 15,000,000
Loss from operations
-4,060,813 -5,652,689 -13,539,614* 11,977,193
Interest income, net
167,311 141,996 101,464* 12,741
(loss) gain on foreign currency transactions
-135,659 -61,735 -1,618,666.5* 172,946
Research and development incentive award
-478,959 -151,604* 5,227
Gain on fair value adjustments
5,379,500 -4,368,869 496,570* -976,678
Total other income
5,890,111 -4,288,608 -1,172,236.5* -796,218
Income (loss) before income taxes
1,829,298 -9,941,297 -14,711,850.5* 11,180,975
Income tax benefit (expense)
-34,794 -34,793 -364,000.5* -81,186
Net income (loss)
1,864,092 -9,906,504 -14,347,850* 11,262,161
Unrealized gain (loss) on foreign currency translation
570,580 49,221 2,394,905.5 -195,818
Total other comprehensive income (loss)
570,580 49,221 2,394,905.5* -195,818
Total comprehensive income (loss)
2,434,672 -9,857,283 -11,952,944.5 11,066,343
Basic EPS
0.41 -4.41 -7.592 6.55
Diluted EPS
-0.77 -4.41 -7.592 6.55
Basic Average Shares
4,536,235 2,246,066 1,574,455 1,719,073
Diluted Average Shares
4,536,235 2,246,066 1,574,455 1,719,073
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Gain on fair valueadjustments$5,379,500 (567.91%↑ Y/Y)Research and developmentincentive award-$478,959 (-56.40%↓ Y/Y)Interest income, net$167,311 (446.50%↑ Y/Y)Total other income$5,890,111 (232.44%↑ Y/Y)(loss) gain on foreigncurrency transactions-$135,659 (-121.55%↓ Y/Y)Income (loss) beforeincome taxes$1,829,298 (194.70%↑ Y/Y)Income tax benefit(expense)-$34,794 (-399.72%↓ Y/Y)Unrealized gain (loss) onforeign currency...$570,580 (144.28%↑ Y/Y)Loss from operations-$4,060,813 (-9.65%↓ Y/Y)Net income (loss)$1,864,092 (195.92%↑ Y/Y)Total othercomprehensive income (loss)$570,580 (144.28%↑ Y/Y)Total operatingexpenses$4,060,813 (-6.99%↓ Y/Y)Total comprehensiveincome (loss)$2,434,672 (175.34%↑ Y/Y)General andadministrative$2,126,918 (-19.10%↓ Y/Y)Restructuring costs$1,236,172 Research and development$697,723 (-59.83%↓ Y/Y)

Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Inc. (NEUP)